explore -WSS

explore

author：hotspot 2025-09-29 23:04:33 - browse：6374

Light micrograph of a fatty liver — Large vacuoles of triglyceride fat, accumulated inside liver cells. Adobe

SAN DIEGO — An experimental obesity drug from Eli Lilly significantly reduced liver fat in a small analysis, supporting further studies of the treatment against nonalcoholic fatty liver disease, an increasingly common condition that lacks approved treatments.

Among 98 patients with nonalcoholic fatty liver disease, those on the highest dose tested of the drug, retatrutide, experienced an 86% decrease in liver fat over 48 weeks, with most of the reduction occurring early on in treatment, according to data presented here at the American Diabetes Association conference Monday.

Additionally, 93% of people on the highest dose achieved resolution of fatty liver disease, defined as having 5% or less liver fat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Virginia high school admissions case could be legal follow
Next article： Pig kidney works a record two months in donated body

WSS

Alabama hospital puts IVF treatments on hold

Why palliative psychiatry is worth discussing

The Readout: Abbvie and Humira, CRISPR in utero, Annovis Bio

Medicare inequities exacerbate Puerto Rico’s health disparities

Alabama hospital puts IVF treatments on hold

New documents shed light on MD Anderson Cancer Institute feud

Wikipedia

explore

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

With competition flaring, obesity drug hits goal in liver disease study

Trump demands the U.S. pay no more for drugs than other countries … again

Ed Silverman on new gene therapies, biosimilars, coffee, and more

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

White House touts steps to stem shortages of cancer treatments

Psychedelics group wrestles with new pharma identity

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

Virginia high school admissions case could be legal follow

A solution to the after

focus

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

He's a Nobel laureate. Critics say he was misleading on Covid

Long Covid needs a new name — and a new frame

The Harvard botanist who searched for psychedelics in the Amazon

Acelyrin, a rare IPO success, stumbles in its first big test

In utero gene editing: an explainer

explore

hotspot

Wikipedia

entertainment